The Effectiveness of Depression Treatment for Adults with ESKD: A Systematic Review

Pavan Chopra,1 Chelsea K. Ayers,2 Jennifer R. Antick,3,4 Devan Kansagara,1,2,5 and Karli Kondo2,6

Abstract

Adults with dialysis-dependent ESKD experience higher rates of depression than the general population, yet efficacy of depression treatments in this population is not well understood. We conducted a systematic review of the benefits and harms of depression treatment in adults with ESKD. We searched multiple data sources through June 2020 for English-language, controlled trials that compared interventions for depression in adults with ESKD to another intervention, placebo, or usual care, and reported depression treatment–related outcomes. Observational studies were included for harms. Two investigators independently screened all studies using prespecified criteria. One reviewer abstracted data on study design, interventions, implementation characteristics, and outcomes, and a second reviewer provided confirmation. Two reviewers independently assessed study quality and resolved any discords through discussion or a third reviewer. Strength of evidence (SOE) was assessed and agreed upon by review-team consensus. We qualitatively analyzed the data and present syntheses in text and tables. We included 26 RCTs and three observational studies. SSRIs were the most studied type of drug and the evidence was largely insufficient. We found moderate SOE that long-term, high-dose vitamin D3 is ineffective for reducing depression severity. Cognitive behavioral therapy is more effective than (undefined) psychotherapy and placebo for depression improvement and quality of life (low SOE), and acupressure is more effective than usual care or sham acupressure in reducing depression severity (low SOE). There is limited research evaluating treatment for depression in adults with ESKD, and existing studies may not be generalizable to adults in the United States. Studies suffer from limitations related to methodologic quality or reporting. More research replicating studies of promising interventions in US populations, with larger samples, is needed.

Systematic Review registry name and registration number: PROSPERO, CRD42020140227

KIDNEY360 2: 558–585, 2021. doi: https://doi.org/10.34067/KID.0003142020

Introduction

The incidence and prevalence of ESKD in the United States have increased steadily over the past four decades (1). Psychiatric and mental-health disorders are more common in adults with ESKD, and include issues such as depression, dementia, delirium, substance abuse, psychoses, anxiety, and personality disorders (2–4). Adults with ESKD experience major depressive disorder at anywhere from three to over six times that of the general US population, depending on the method of assessment, and depression is the most common mental-health issue in this population (5,6).

The effect of depression can be extremely detrimental for a wide range of patient outcomes for those with ESKD. For instance, adults with ESKD who have depressive symptoms have a 12% higher rate of hospitalization than those without (7), and those with ESKD and psychiatric issues have a 40%–50% increased risk of all-cause mortality (8). Comorbid depression is associated with increased emergency-department visits, hospitalizations, hospital length of stay, suicide, and treatment nonadherence, along with decreased quality of life (QoL) and sleep (8–13).

There are no established guidelines for treating depression in adults with ESKD. Less than 25% of those on dialysis who are diagnosed with moderate or severe depression actually undergo treatment (12,14,15). There are few studies of treatment efficacy in this population and, while some studies include only participants with clinical depression, others include any adults with ESKD. Psychosocial treatments and cognitive behavioral therapy (CBT) are commonly used; however, interventions vary widely, the evidence is limited, and findings may vary on the basis of the presence and severity of depression.

Given the wide variation in depression treatment options for adults with ESKD, it is vital to understand the depression treatment–related outcomes for those in this population suffering from clinical depression. The purpose of this review is to better understand the benefits and harms of treatment for depression in these adults.

1Department of Medicine, Oregon Health and Science University, Portland, Oregon
2Evidence Synthesis Program, Veterans Affairs Portland Health Care System, Portland, Oregon
3School of Graduate Psychology, Pacific University, Hillsboro, Oregon
4Legacy Good Samaritan Medical Center, Portland, Oregon
5Center to Improve Veteran Involvement in Care, Veterans Affairs Portland Health Care System, Portland, Oregon
6Research Integrity Office, Oregon Health and Science University, Portland, Oregon

Correspondence: Dr. Karli Kondo, Veterans Affairs Portland Health Care System, Mail Code R&D 71, 3710 SW US Veterans Hospital Road, Portland, OR 97239-2999. Email: kondo@ohsu.edu

www.kidney360.org Vol 2 March, 2021
**Materials and Methods**

This systematic review was part of a larger review commissioned by the Veterans Health Administration (VHA) (16). A protocol describing the review plan was posted to PROSPERO, a systematic review registry, before study initiation (CRD42020140227). Our methods and reporting follow Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines (17). See Supplemental Table 1 for the scope and parameters of the systematic review.

**Data Sources and Searches**

To identify trials examining the treatment of depression in adults with ESKD, we searched Ovid MEDLINE, PsycINFO, Elsevier EMBASE, and the Ovid Evidence-Based Medicine Reviews (Cochrane Database of Systematic Reviews, Database of Abstracts of Reviews of Effects, Health Technology Assessment, Cochrane CENTRAL, etc.) from database inception through June 2020. We reviewed the bibliographies of systematic reviews and other relevant articles, and contacted experts to identify additional studies. To identify unpublished literature, we searched the VHA Health Services Research and Development Service, ClinicalTrials.gov, and the World Health Organization International Clinical Trials Registry Platform. Search strategies were developed in consultation with a research librarian and peer reviewed by another research librarian using the instrument for Peer Review of Search Strategies (see Supplemental Appendix 1) (18).

**Study Selection**

Studies were eligible if they (1) included adults with dialysis-dependent ESKD not slated for transplant and depression, defined by established thresholds for chronically ill populations (19–23); (2) directly compared any pharmacologic or nonpharmacologic treatments for depression to placebo, wait-list control, or other intervention; (3) were randomized controlled trials (RCTs) or nonrandomized...
| Author (Reference); N Randomized; Years of Enrollment | Intervention/ Comparator | N Sites; Study Setting; Country/US Region | Clinical Characteristics/ Demographics of Study Population | Inclusion Criteria | Depression Screening Tool(s) | Baseline Depression Score, Mean (SD), T versus C |
|------------------------------------------------------|--------------------------|------------------------------------------|----------------------------------------------------------|------------------|-----------------------------|--------------------------------------------------|
| **Pharmacologic**                                    |                          |                                          |                                                          |                  |                             |                                                  |
| Blumenfield et al. (30); N=14; Yr NR                | Fluoxetine versus placebo| 2 sites; hospital dialysis centers; New York, NY | NR                                                       | Cutoff for inclusion: HAM-D score ≥16; Other inclusion criteria: age 18–70, normal liver function | HAM-D; BDI-II; MADRS; BSI; VAS                      | NR                                               |
| Friedli et al. (33); N=30; April 2013–May 2015a      | Sertraline versus placebo | Multisite (5); renal units; England      | 12% Female; age (SD), 61.7 (13.2) yr; race, 67% White, 13% Black, 13% Asian, 7% mixed | Cutoff for inclusion: BDI-II score ≥16, MINI mild to moderate MDD, MADRS score ≥18; Other inclusion criteria: excluded if already on SSRIs (56) | BDI-II; MINI; MADRS                              | MADRS: 24.5 (4.5) versus 25.3 (4.2)             |
| Gharekhani et al. (35); N=54; Yr NR                 | ω-3 Fatty acid versus placebo | 2 sites; HD centers; Tehran, Iran        | HD duration (SD), 70.7 (45.1) mo, 4 h, 2–3× per wk; 48% female; age (SD), 56.8 (13.09) yr | Cutoff for inclusion: BDI-II score ≥16; Other inclusion criteria: adults, HD ≥3 mo and all had same HD Rx | BDI-II                                               | 23.52 (7.49) versus 21 (4.72); median (IQR): 22 (17–28) versus 21 (16.50–22.75) |
| Haghighat et al. (36); N=49; Yr NR                  | Synbiotic supplement versus probiotic; supplement versus placebo | 1 site; hospital HD center; Iran         | 52% Female; age (SD), 46.64 (10.69) yr                     | Cutoff for inclusion: ≥8; Other inclusion criteria: stable patient on HD with arteriovenous fistula, age 50–65, HD 3× per wk for ≥3 mo | HADS                                                | 9.16 (1.11) versus 9.77 (1.77) versus 9.20 (1.30); P=0.63 |
| Hosseini et al. (38); N=44; Yr NR                   | Citalopram versus psychologic training | Single site; hospital HD center; Iran    | 55% Female; age (SD), 52.3 (15.6) yr                      | Cutoff for inclusion: HADS ≥8; Other inclusion criteria: NA | HADS                                                | 9.42 (3.11) versus 9.58 (3.47)                  |
| Mehrotra et al. (44); N=120; 2017                    | Sertraline versus CBT    | Multisite (3 states); 41 dialysis facilities; United States, NM, TX, WA | Median time on dialysis, 31 mo; mean HD session length (SD), 3.9 (0.4) h; history of major depression, 42%; 43% female; age (SD), 51 (13) yr; race/ethnicity, 43% White, 28% Black, 28% Hispanic, 8% Native American, 12% other; education, 40% ≤high school | Cutoff for inclusion: BDI-II ≥15, then confirmed by MINI; Other inclusion criteria: age ≥21, ESKD, on HD for ≥3 mo | BDI-II; MINI; QIDS-SR; QIDS-C                  | QIDS-C mean (range): SERT 10.9 (9.6–12.1) versus CBT 12.2 (11.0–13.5); BDI-II mean (range): SERT 25.8 (23.3–28.4) versus CBT 26.2 (23.6–28.8) |
| Author (Reference); N Randomized; Years of Enrollment | Intervention/Comparator | N Sites; Study Setting; Country/US Region | Clinical Characteristics/ Demographics of Study Population | Inclusion Criteria | Depression Screening Tool(s) | Baseline Depression Score, Mean (SD), T versus C |
|-----------------------------------------------------|-------------------------|------------------------------------------|--------------------------------------------------------|-------------------|--------------------------|---------------------------------------------|
| Taraz et al. (46); N=50; Yr NR                      | Sertraline versus placebo | Single site; outpatient HD clinic; Tehran, Iran | HD for 4 h 3× per wk, 43%; time on HD, 42 mo; 60% female; age (SD), 60 (22) yr; all others NR | Cutoff for inclusion: BDI-II ≥16 | BDI-II | 29 (13) versus 23 (11); P=0.24 |
| Wang et al. (49); N=160; 2013                        | Radix Bupleuri herbal supplement versus placebo | Single site; Dalian, Northeast China | HD duration (SD), 26 (13) versus 29 (15) mo; 75% female; education, approximately 86% <9 yr; concurrent antidepressant medication use, 51% versus 46% | Cutoff for inclusion: NR | MADRS | 23.9 (7.8) versus 24.6 (7.4) |
| Wang et al. (50); N=746; Yr NR                       | Vitamin D3 versus placebo | 3 sites; dialysis centers, HD and PD, outpatient; Southeast China | 39% Female; age, 54% 18–64 yr; 46% ≥65 yr; other demographics, NR | Cutoff for inclusion: BDI-II ≥16 | BDI-II | 22.7 (4.3) versus 21.9 (5.4); P=0.31 |
| Nonpharmacologic                                    | Al Saraireh et al. (27); N=130; 2017 | CBT versus PSE Multisite; 5 hospital dialysis units; Jordan | Dialysis duration, NR; approximately 50% female; age (SD), 52 (10.7) yr; education, 71%; high school; employment, 82% unemployed; race/insurance, NR | Cutoff for inclusion: NR | HAM-D | PSE 19.6 (5.4) versus CBT 19.5 (5.4); no difference, t (103)=-0.13; P=0.89 |
| Author (Reference); N Randomized; Years of Enrollment | Intervention/Comparator | N Sites; Study Setting; Country/US Region | Clinical Characteristics/Demographics of Study Population | Inclusion Criteria | Depression Screening Tool(s) | Baseline Depression Score, Mean (SD), T versus C |
|---|---|---|---|---|---|---|
| Babamohamadi et al. (28); N=60; Yr NR | Quran versus TAU | Single site; hospital dialysis ward; Iran | 43% Female; age (SD), 53.3 (11.4) yr; race, NR; education, 75% less than diploma; employment, NR (56% “poor”); insurance, NR | Cutoff for inclusion: BDI-II score ≥20 Other inclusion criteria: age 18–65, command of Arabic, HD for ≥6 mo, hemodynamically stable | BDI-II | 33.6 (6.7) versus 29.3 (9.0); mean difference, -4.3 (95% CL -8.7 to 0.0); P=0.05 |
| Beizaee et al. (29); N=80; 2015–2016 | Guided imagery versus TAU | Single site; HD center; Iran | 41% Female; age (SD), 47.21 (8.34) yr; education, 46% secondary school; employment, 25% unemployed | Cutoff for inclusion: NR Other inclusion criteria: HD 3× per wk for ≥6 mo, age 35–65 yr, read/write in Farsi, intact cognitive functions on the basis of AMT | HADS | 10.82 (2.70) versus 11.55 (2.29) |
| Cukor et al. (31); N=65; Yr NR | CBT versus wait list | 2 sites; dialysis units; Brooklyn, NY | 73% Female; age, NR; race, 94% Black; education (SD), 11.2 (3.4) yr; employment, 83% unemployed; insurance, NR | Cutoff for inclusion: BDI-II score ≥10 Other inclusion criteria: ESKD with HD for ≥6 mo | SCID-I; BDI-II; HAMD | SCID-I with major depression: 55% versus 42% BDI-II: 25.3 (9.3) versus 21.4 (8.9) HAMD: 15.0 (6.2) versus 13.5 (5.0) BDI-II: 24.2 (9.7) versus 27.3 (10.7); P=0.15 MINI: 6.4 (1.3) versus 6.4 (1.2); P=0.96 |
| Duarte et al. (32); N=90; Yr NR | CBT versus psychotherapy | 2 sites; dialysis units; Brazil | HD, 3× per wk for 4 h average; 63% female; age (SD), 52.4 (15.9) yr; race, 78% White; education, 83% ≤primary school; employment/insurance, NR | Cutoff for inclusion: MDD with MINI Other inclusion criteria: ESKD with HD for ≥3 mo | BDI-II; MINI | BDI-II: 24.2 (9.7) versus 27.3 (10.7); P=0.15 MINI: 6.4 (1.3) versus 6.4 (1.2); P=0.96 |
| Frih et al. (34); N=41; 2012–2013a | Exercise (endurance-resistance training) versus TAU | Single site; hospital; Tunisia | HD, 4 h 3×/wk; HD duration, 72.7 (12.7) mo; age (SD), 64.2 (3.4) yr; 0% female; other demographics, NR | Cutoff for inclusion: NR Other inclusion criteria: excluded chronic lung disease, ischemic heart disease, uncontrolled arrhythmias or hypertension, hemodynamically unstable, or musculoskeletal disorders, those regularly exercising | HADS | Approximately 12 versus approximately 13 (exact scores NR) |
| Author (Reference); N Randomized; Years of Enrollment | Intervention/ Comparator | N Sites; Study Setting; Country/US Region | Clinical Characteristics/ Demographics of Study Population | Inclusion Criteria | Depression Screening Tool(s) | Baseline Depression Score, Mean (SD), T versus C |
|----------------------------------------------------|--------------------------|-------------------------------------------|----------------------------------------------------------|-----------------|----------------------------|-----------------------------------------------|
| Heshmatifar et al. (37); N=70; 2013               | Benson relaxation technique versus TAU | Single site; hospital HD unit; Iran | HD, 3× per wk; 18% female; age, 9% 18–35, 33% 35–45, 45% 45–55, 15% 55–65 yr; race, NR; education, 94% ≤high school; employment, 42% unemployed; insurance, NR | Cutoff for inclusion: NR Other inclusion criteria: aged 18–65 yr, HD 3× per wk for ≥6 mo, regular patient of the center | BDI-II | 32.46 (9.86) versus 30.58 (9.24) |
| Kargar Jahromi et al. (55); N=60; 2014            | Telednursing versus TAU | Single site; hospital HD unit; Iran | T versus C:56% versus 40% female; education, 4% >high school; unemployed, 60% versus 44%; other demographics, NR | Cutoff for inclusion: NR DASS-21 16.60 (1.50) versus 16.72 (1.83); P=0.40 | Other inclusion criteria: aged 18–65 yr; HD 3–4 h 3× per wk for ≥6 mo; no transplants, hospitalizations, or antidepressant Rx | 16.60 (1.50) versus 16.72 (1.83); P=0.40 |
| Kalani et al. (39); N=96; 2011                   | Acupressure versus sham versus TAU | 3 sites; HD centers; Iran | 44% female; age (SD), 53.4 (13.9); race, NR; education, 31% nonliterate; employment, 50% unemployed, 41% retired; insurance, NR | Cutoff for inclusion: BDI-II score ≥10 Other inclusion criteria: ESKD diagnosis, age ≥18, HD for ≥3 mo, mental and psychologic ability to participate | BDI-II | T 27.5 (9.1) versus sham 25.7 (7.7) versus C 24.6 (8.6) |
| Kouidi et al. (40); N=50; Yr NR                   | Exercise training versus sedentary control | Single site; hospital renal unit; Greece | HD, 3× per wk for 4 h; 42% female; age (SD), 46.3 (11.2) yr; education, 10.2 (3.4) yr; employment, 17% unemployed; race/insurance, NR | Cutoff for inclusion: NR Other inclusion criteria: ESKD, 4 h HD 3× per wk for ≥6 mo | BDI-II; HADS | BDI-II: 22.29 (6.71) versus 22.30 (6.81) HADS: 10.63 (2.60) versus 10.40 (2.50) |
| Lerma et al. (41); N=60; Yr NR                    | CBT versus waiting list | 2 sites; HD units; Mexico City, Mexico | HD, 3× per wk for 3–4 h; 52% female; age (SD), 41.8 (14.7) yr; education, 36% elementary; employment, 26% unemployed; race/insurance, NR | Cutoff for inclusion: BDI-II score of 10–29 points Other inclusion criteria: ESKD, literate, no psychiatric illness, regular attendance of HD sessions 3–4 h HD 3× per wk for ≥6 mo | BDI-II | 13.6 (7.6) versus 15.8 (10.0) |
| Li et al. (42); N=72; 2018–2019                   | Home nursing visits versus telephone follow-up | Single site; hospital; Hainan, China | Dialysis duration (SD), 22.68 (10.25) mo; 44% female; age (SD), 55.8 (6.2) yr; education, 56% ≤middle school | Cutoff for inclusion: BDI-II score of 10-29 Other inclusion criteria: ESKD, literate, no psychiatric illness, regular attendance of HD sessions 3–4 h HD 3× per wk for ≥6 mo | Zung SDS | 63.34 (6.28) versus 64.27 (6.11); P=0.53 |
Table 1. (Continued)

| Author (Reference); N Randomized; Years of Enrollment | Intervention/Comparator | N Sites; Study Setting; Country/US Region | Clinical Characteristics/Demographics of Study Population | Inclusion Criteria | Depression Screening Tool(s) | Baseline Depression Score, Mean (SD), T versus C |
|------------------------------------------------------|--------------------------|------------------------------------------|----------------------------------------------------------|-------------------|----------------------------|-----------------------------------------------|
| Liao et al. (43); N=128; 2017                        | Comprehensive nursing versus conventional care | Single site; hospital; Hainan, China | HD duration (SD), 43.56 (13.95) mo; 44% female; age (SD), 52.87 (10.46) yr; education, 57% < high school | Cutoff for inclusion: NR Other inclusion criteria: age ≥ 18, on HD ≥ 3 mo for CRF/ESKD | Zung SDS | 60.83 (22.67) versus 64.02 (28.58); P = 0.49 |
| Rahimipour et al. (45); N=50; Yr NR                  | Hope therapy versus control | Multisite; hospitals; Iran | HD, 2–3× per wk for 4 h; 48% female; age (SD), 47.82 (15.12) yr; race/education/employment/insurance, NR | Cutoff for inclusion: NR Other inclusion criteria: aged 18–65 yr; HD 2–3× per wk for ≥ 3 mo; not taken medication for depression, anxiety, or stress | DASS-21 | 13.36 (3) versus 13.64 (3.5); P = 0.76 |
| Thomas et al. (47); N=41; 2016                        | MBSR versus TAU | Single site; hospital HD unit; Montreal, Canada | 33% Female; age (SD), 65 (13) yr; race, 49% White, 51% non-White; education, 63% ≥ high school; employment/insurance, NR | Cutoff for inclusion: PHQ-9 score ≥ 6 and/or GAD-7 score ≥ 6 Other inclusion criteria: on maintenance HD, spoke English or French | PHQ-9 | 12.7 (4.2) versus 11.9 (5.8) |
| Tsay et al. (48); N=108; Yr NR                       | Acupressure versus TEAS versus control | 4 sites; hospital dialysis centers; Northern Taiwan | Duration HD (SD), 50.06 (44.15) mo; 66% female; age (SD), 58.16 (12.19) yr; employment, 76% retired or unemployed; race/education, NR HD 2× per wk; 61% female; age (SD), 50.06 (7.39) yr; education, 78% ≥ high school; insurance, 6% uninsured; employment/race, NR | Cutoff for inclusion: BDI-II score ≥ 10 Other inclusion criteria: ESKD diagnosis, age ≥ 18, HD for ≥ 3 mo, fatigue, PSQI score ≥ 5 | BDI-II | Acupressure 20.37 (10.65) versus TEAS 18.20 (11.11) versus C 21.61 (11.69) |
| Widyaniningrum and Djarwoto (51); N=36; 2012          | Latihan Pasrah Diri versus control | Single site; hospital HD unit; Java, Indonesia | | Cutoff for inclusion: BDI-II ≥ 16 Other inclusion criteria: aged 18–60 yr, CKD adults on 2× per wk HD for ≥ 3 mo | BDI-II | 23 (5.34) versus 23.39 (5.02) |
| Author (Reference); N Randomized; Years of Enrollment | Intervention/ Comparator | N Sites; Study Setting; Country/US Region | Clinical Characteristics/ Demographics of Study Population | Inclusion Criteria | Depression Screening Tool(s) | Baseline Depression Score, Mean (SD), T versus C |
|-----------------------------------------------------|--------------------------|------------------------------------------|-----------------------------------------------------------|-------------------|---------------------------|----------------------------------|
| **Harms-only studies**                               |                          |                                          |                                                            |                   |                           |                                   |
| Assimon et al. (57); N=65,654; 2007–2014            | SSRIs with higher QT-prolonging potential\(^b\) versus SSRIs with lower QT-prolonging potential\(^c\) | US Renal Data System Database | 57% Female; age (SD), 67.0 (17.2) yr; race, 36% Black; ethnicity, 19% Hispanic | Inclusion: new SSRI users who received HD during the 180 d before SSRI initiation and had continuous Medicare Part A, B, and D coverage. Excluded: <18 yr at start of baseline, dialysis vintage ≤90 d at the start of baseline, presence of an implantable automatic cardiac defibrillator, receipt of hospice care during the baseline period, and missing demographic data | NA | NA |
| Guirguis et al. (56); N=41; 2013–2015\(^a\)          | SSRI observational       | Multisite; NR; England                  | 37% Female; age (SD), 62 (16) yr; race, 27% non-White     | ASSertID study participants who were excluded from the RCT (33) phase because they were already on SSRIs | TBI-II, PHQ-9 | BDI-II: 26 PHQ-9: 12 |
| Vangala et al. (58); N=54,032; 2009–2015            | SSRI versus no SSRI      | US Renal Data System Database           | Patients versus controls: female, 58% versus 52%; age (SD), 71 (12) versus 61 (14) yr; 29% versus 49% Black; 22% versus 19% Hispanic; 39% versus 25% non-Hispanic White | Inclusion: Medicare Part D, receipt of a low-income subsidy, RRT start date, demographic data, a Medical Evidence Report from 1995 or later, >90 d HD | NA | NA |

\(^a\)Part of the larger ASSertID study.
\(^b\)Citalopram and escitalopram.
\(^c\)Fluoxetine, fluvoxamine, paroxetine, and sertraline.
controlled trials in any setting (for harms outcomes, we also included observational studies); (4) assessed patient outcomes of interest (e.g., depression symptom severity, suicidal ideation, QoL); and (5) were published in English. We excluded studies examining adults with AKI or those with CKD stages 1–4. See Supplemental Appendix 2 and Supplemental Table 1 for complete selection criteria. All studies were reviewed for inclusion by two independent reviewers at the title/abstract and full-text levels. Discords were resolved through consensus or consultation with a third reviewer.

Data Abstraction and Quality Assessment

From included studies, we abstracted details on study design, sample size, setting, population characteristics, participant selection criteria, and intervention details (including the dosage, timing, and administration methods; duration of treatment and follow-up; outcomes; and relevant harms). Data from studies meeting inclusion criteria were abstracted by one reviewer and confirmed by an additional reviewer.

Two reviewers independently assessed the methodologic quality of each study using criteria established by the US Preventive Services Taskforce and adapted for depression interventions (24–26). Disagreements were resolved by consensus or a third reviewer.

Data Synthesis and Analysis

We qualitatively synthesized the evidence for each treatment category and outcome of interest. We were unable to quantitatively synthesize the evidence because there were too few studies examining the same intervention and reporting the same outcome measure (52).

Using an established method by Berkman et al. (53), for each intervention, we assessed the overall strength of evidence (SOE) that considers study limitations, directness, consistency, precision, and reporting bias to classify the SOE for each outcome independently as high, moderate, low, or insufficient; we used separate guidance for the applicability (external validity) of the evidence to the clinical question (54). Supplemental Table 2 describes SOE domains and grading in more detail.

Results

We reviewed 8050 titles and abstracts, 192 of which qualified for full-text review. Of those, we included a total of 26 RCTs; nine examined pharmacologic interventions and 17 examined nonpharmacologic interventions for the treatment of depression in adults with ESKD. We also included three observational studies reporting harms of selective serotonin reuptake inhibitors (SSRIs; see Figure 1 for literature flow, and Table 1 for study characteristics).

Pharmacologic Treatments

SSRIs

**SSRIs versus Placebo.** Three studies comparing SSRIs with placebo report conflicting findings and provide insufficient evidence to draw conclusions about their effectiveness in treating depression in adults with ESKD (see Table 2 for study results and Table 3 for SOE ratings). Two small US RCTs (one 8-week, poor-quality trial of fluoxetine [N=14] [30], and one recent, fair-quality, 6-month trial of sertraline [A Study of Sertraline in Dialysis; ASSertID; N=30] [33]) found no difference in depressive-symptom reduction between those assigned to SSRIs or placebo. One fair-quality, 12-week, Iranian RCT (N=50) (46) found that participants who received sertraline reported a significant reduction in depressive symptoms compared with placebo. Small sample sizes and differences in depression assessment tools and statistical analyses detracted from the quality of these studies (see Table 4 for quality ratings).

**SSRIs versus Active Comparators.** SSRIs versus CBT A recent, fair-quality, multisite, head-to-head RCT (N=120) in the United States (A Trial of Sertraline versus Cognitive Behavioral Therapy for ESKD Adults with Depression; ASCEND [44]) provides low-strength evidence that sertraline and CBT are similar when used for the reduction of depressive symptoms (Tables 3 and 4). Over the 12-week study period, both groups improved significantly. Participants who received sertraline experienced significantly greater improvement (effect estimate, −1.85; 95% CI, −3.55 to −0.16; Table 2) when assessed by a clinician (Quick Inventory of Depressive Symptomatology). There was no difference between groups in self-reported symptoms (i.e., Beck Depression Inventory-II; effect estimate, −2.9; 95% CI, −6.7 to 0.8; Table 2). SSRIs versus Psychologic Training

A small (N=44), 3-month, poor-quality RCT (38), conducted in Iran, provides insufficient evidence for the comparison of citalopram to “psychologic training” in participants with ESKD and depression (Tables 3 and 4). Although both arms reported a reduction in depressive symptoms, there was no difference between groups (Table 2).

**Harms of SSRIs.** Adverse events (AEs) reported in the included trials of SSRIs in adults with depression and ESKD were similar in type and frequency to those reported by the general population on SSRIs (59). One trial reported a higher rate of dropout due to AEs associated with sertraline (33% versus 0%; P=0.04) (33). Across all four trials (30,33,44,46), a wide range of AEs (e.g., nausea, headaches, dizziness) were reported by participants in both treatment and control groups, but they were not consistently nor uniformly reported (Table 5).

Additionally, three observational studies focused specifically on potential harms related to SSRIs in adults with ESKD and depression (Table 6). Two examined Medicare beneficiaries who received SSRIs that were included in the US Renal Data System registry. A case-control study (N=54,032) found that SSRIs increased the risk of hip fracture regardless of dose or duration (58), and the second (57), a retrospective cohort study (N=65,654), found that adults, especially older adults and women, taking SSRIs with higher QT-prolonging potential (i.e., citalopram and escitalopram) were at higher risk for sudden cardiac death (adjusted hazard ratio, 1.18; 95% CI, 1.05 to 1.31). The final study was a follow-up to the ASSertID RCT (33) that examined SSRI practice patterns in adults with ESKD, and included participants who were already on SSRIs at baseline (N=41). Findings suggest poor medication management and both under- and over-treatment (56).
### Table 2. Efficacy of interventions from randomized controlled trials for depression in adults with ESKD

| Author (Reference); Year; N Randomized (T versus C); Duration of Treatment and Follow-Up | Treatment | Comparator | Findings, Treatment versus Comparator | Quality |
|---|---|---|---|---|
| **Pharmacologic**<br>SSRIs versus control<br>Blumenfield et al. (30); 1997; 7 versus 7; Tx=8 wk, F/U=8 wk | Fluoxetine: 20 mg/d for 8 wk | Matched placebo | Mean change from baseline (at 4 wk; at 8 wk):<br>BDI-II: −12 versus −4.17 (<i>P=0.05</i>); −9.57 versus −8.8 (<i>P=0.91</i>)<br>BSI: −6.29 versus 0.2 (<i>P=0.04</i>); −4.43 versus −3.2 (<i>P=0.88</i>)<br>HAM-D: no 4 wk assessment; −9.00 versus −7.5 (<i>P=0.72</i>)<br>MADRS: −7.20 versus −6.75 (<i>P=0.93</i>); −11.14 versus −6.67 (<i>P=0.45</i>)<br>VAS: −210.0 versus −58.3 (<i>P=0.37</i>); −303.0 versus −140 (<i>P=0.45</i>)<br>Electronic VAS: −262.4 versus 5.6 (<i>P=0.05</i>); −389.0 versus −87.8 (<i>P=0.13</i>)<br> | NA | Poor |
| Friedli et al. (33); 2017; 15 versus 15; Tx=6 mo, F/U=6 mo | Sertraline: 100 mg/d (50 mg/d to start; dose could be increased to maximum at 2 and 4 mo) | Matched placebo | MADRS between-group difference at 6 mo: −0.67 (95% CI, −5.7 to 4.4)<br>Within-groups decrease significant for both groups<br>Mean change at study end:<br>MADRS: −14.5 (95% CI, −20.2 to −8.8) versus −14.9 (95% CI, −18.4 to −11.5)<br>BDI-II: −15.7 (95% CI, −24.3 to −7.1) versus −13.0 (95% CI, −19.6 to −6.4)<br> | NA | Fair |
| Taraz et al. (46); 2013; 25 versus 25; Tx=12 wk, F/U=12 wk | Sertraline: 100 mg/d (50 mg/d for first 2 wk) | Matched placebo | BDI-II scores (SD) for baseline, 6 wk, 12 wk, Δ baseline to 12 wk: sertraline, 29 (13), 21 (11.5), 15 (5.5), −11.3 (5.8) versus placebo, 23 (11), 22.5 (8.5), 22.5 (9), −0.5 (5); comparison Δ baseline to 12 wk between groups, <i>P=0.001</i> | NA | Fair |
| Author (Reference); Year; N Randomized (T versus C); Duration of Treatment and Follow-Up | Treatment | Comparator | Findings, Treatment versus Comparator | Depression | Other outcomes | Quality |
|---|---|---|---|---|---|---|
| SSRIs versus active comparator | Citalopram: 20 mg/d | Psychologic training: six 1-h sessions on kidney-disease education, problem solving, stress management, and muscle-relaxation techniques | Postintervention HADS (SD): 6.26 (4.18) ($P = 0.001$) versus 7.33 (4.80) after training ($P = 0.04$); no difference between groups ($P = 0.16$) Between-groups mean differences also NS ($P = 0.65$) QIDS-C scores (SD): 5.9 (4.5) versus 8.1 (5.1) Effect estimate: $-1.85$ (95% CI, $-3.55$ to $-0.16$) BDI-II scores: 14.1 (95% CI, 11.2 to 17.0) versus 18.7 (95% CI, 15.2 to 22.2) Effect estimate: $-2.9$ (95% CI, $-6.7$ to 0.8) | NA | Poor |
| Mehrotra et al. (44); 2019; 60 versus 60; Tx=12 wk, F/U=12 wk | Sertraline: 200 mg/d unless limited by AEs (titration began at 25 mg/d and adjusted each visit) | CBT: ten 60-min sessions during HD for 12 wk, adapted for maintenance HD population | NA | Fair |
| Supplements versus placebo | $\Omega$-3 Fatty acids: 1800 mg/d for 4 mo | Matched placebo: paraffin oil capsules | Mean end of study BDI-II (SD): 13.44 (5.66) versus 20.33 (7.56) Difference (SD): $-10.08$ (8.07) versus $-0.88$ (8.41); $P = 0.001$ Within groups: Significant decrease ($P < 0.001$) versus no significant change End-of-treatment HADS-D scores (SD): symbiotic 6.92 (1.27) versus placebo 9.40 (1.5); $P < 0.001$ Symbiotic (SD) 6.92 (1.27) versus probiotic 8.48 (1.61); $P = 0.011$ Mean difference in HADS-D scores from baseline: symbiotic, $-2.24$ (95% CI, $-3.29$ to $-1.38$); probiotic, $-1.28$ (95% CI, $-2.05$ to $-0.53$); placebo, 0.20 (95% CI, $-0.43$ to 0.76); $P = 0.001$ Symbiotic versus placebo (post hoc); $P < 0.001$ | NA | Poor |
| Haghighat et al. (36); 2019; 16 versus 18 versus 15; Tx=12 wk, F/U=12 wk | Symbiotic supplement: L. acidophilus strain T16, B. bifidum strain BIA-6, B. lactis strain BIA-7, B. longum strain BIA-8 (2.7×10^7 CFU/g each) per 5 g sachet + prebiotic (5 g FOS + 5 g GOS + 5 g inulin per three 5 g sachets); probiotic supplement same as above, except prebiotics replaced with placebo | Matched placebo | NA | Good |
| Author (Reference); Year; N Randomized (T versus C); Duration of Treatment and Follow-Up | Treatment Comparator | Findings, Treatment versus Comparator | Quality |
|---|---|---|---|
| **Wang et al. (49); 2015; 80 versus 80; Tx and F/UI=3 mo** | **Radix Bupleuri herbal supplement: 1 g root powder in capsule daily** | **Placebo** | **Mean (SD) MADRS scores at 3 mo: 13.32 (8.25) versus 16.73 (9.46)**  
**Change from baseline MADRS: -11.36 versus -2.24; Mean difference, 4.72 (95% CI, 0.69 to 9.12); P=0.02**  
**QoL (RAND-36): change from baseline 14.21 versus 21.12; MD, -4.61 (95% CI, -11.32 and 2.75); P=0.04** | **Poor** |
| **Wang et al. (50); 2019; 373 versus 373; Tx and F/UI=52 wk** | **High-dose oral vitamin D3: 52-wk treatment of 50,000 IU/wk** | **Matched placebo** | **No between-groups difference in Δ values**  
**Within-group BDI-II scores (SD), baseline to end of study: 22.7 (4.3) to 19.6 (3.7) (P=0.02) versus 21.9 (5.4) to 20.8 (5.1) (P=0.03)** | **Fair** |
| **Nonpharmacologic**  
**Cognitive behavioral therapy**  
**Al Saraireh et al. (27); 2018; 65 versus 65; Tx=12 wk; F/UI=12 wk** | **CBT: seven individual 1-h sessions following the traditional CBT sessions protocol** | **PSE: 7 individual 1-h sessions** | **Post-test HAM-D scores (SD): 15.0 (5.5) versus 11.1 (2.3)**  
**Between-groups depression scores favored PSE (t=4.68; P<0.01) over CBT** | **NA** |
| **Cukor et al. (31) (crossover); 2014; 38 versus 27; Tx=3 mo, F/UI=6 mo** | **CBT: individual 60-min CBT chairside during dialysis; modified for population; 10 sessions over 3 mo** | **Wait-list control** | **BDI-II: mean change score (SD) during treatment: -11.7 (1.5) points (P<0.001) versus -4.8 (1.4) points (P<0.001)**  
**Raw mean (SD) change: 24.7 (9.8) to 11.7 (9.8) versus 14.5 (8.5) to 9.1 (6.5)**  
**Mean (SD) change in BDI-II score in untreated group during wait-list period: -6.7 (1.7) points; P<0.001 (raw mean change, 21.9 [8.9] to 14.5 [8.5]).**  
**Magnitude of improvement greater in the intervention-first group versus wait-list condition (P=0.03)**  
**HAM-D: the difference in mean change score between treated and untreated groups was highly significant (P<0.001)**  
**SCID-I: between groups not reported** | **Fair** |

KIDNEY 360: 2: 558–585, March, 2021  
Depression Treatment for Adults with ESKD, Chopra et al. 569
| Author (Reference); Year; N Randomized (T versus C); Duration of Treatment and Follow-Up | Treatment | Comparator | Findings, Treatment versus Comparator |
|---|---|---|---|
| **Duarte et al. (32); 2009; 46 versus 44; Tx=12 wk, F/L=9 mo** | CBT: group CBT sessions, 90 min 1× per wk for 12 wk, followed by 6 mo maintenance with monthly meetings | Individualized psychotherapy (routinely available in dialysis unit) 30–50 min 1× per wk for 12 wk; followed by as-needed psychologic care for 6 mo | BDI-II: after 3 mo, 14.1 (SD, 8.7) versus 21.2 (SD, 9.1); P=0.001; after 9 mo, 10.8 (SD, 8.8) versus 17.6 (SD, 11.2); P=0.002 |
| | | | Suicide Risk Module (MINI): baseline 2.2 (SD, 5.1) versus 1.4 (SD, 3.5); P=0.23; after 3 mo, 1.2 (SD, 4.2) versus 0.7 (SD, 1.9); P=0.43; after 9 mo, 0.6 (SD, 1.2) versus 0.6 (SD, 2.0); P=0.95 |
| | | | MINI: the mean change from baseline (SE) favored intervention |
| | | | After 3 mo: 4.5 (SE, 0.4) versus 2.1 (SE, 0.6); P<0.001 |
| | | | After 9 mo: 4.4 (SE, 0.4) versus 2.9 (SE, 0.5); P=0.03 |
| | | | Overall reduction, within-group comparison: significant reduction within T group (P=0.007) versus C (P=0.13) |
| | | | QoL: CBT group significantly improved several dimensions of KDQOL. Between-groups significant improvement in burden of kidney disease, quality of social interaction, sleep, overall health, and mental component summary dimensions |
| | | | Overall QoL (PLC): baseline, 99.4 (SD, 21.3) versus 91.5 (SD, 19.5); P=0.20 |
| | | | After 5 wk, 109.6 (SD, 21.1) versus 94.0 (SD, 21.0); P=0.02 |
| | | | After 9 wk, 112.5 (SD, 23.8) versus 91.3 (SD, 22.5); P=0.004 |
| | | | Overall within-group P=0.001 versus P=0.663; Cohen d=0.93 (large) |
| **Lerma et al. (41); 2017; 38 versus 22; Tx=5 wk, F/L=9 wk** | CBT: 5 group sessions (2 h), 1× per wk after HD session | Waiting list | End-of-treatment BDI-II, 10.2 (SD, 8.2) versus 15.0 (SD, 10.9); P=0.08 |
| | | | Follow-up BDI-II: 7.1 (SD, 7.2) versus 14.7 (SD, 9.7); P=0.003 |
| | | | Within-group reduction in scores: P<0.001 versus P=0.87 |
| | | | RR of reducing depressive symptoms (between groups), 1.7 |
| | | | Adjusted RR between groups for depression, 0.33 (95% CI, 0.05 to 0.55; 33% clinical utility) |
| | | | Overall QoL (PLC): baseline, 99.4 (SD, 21.3) versus 91.5 (SD, 19.5); P=0.20 |
| | | | After 5 wk, 109.6 (SD, 21.1) versus 94.0 (SD, 21.0); P=0.02 |
| | | | After 9 wk, 112.5 (SD, 23.8) versus 91.3 (SD, 22.5); P=0.004 |
| | | | Overall within-group P=0.001 versus P=0.663; Cohen d=0.93 (large) |
| **Nursing interventions** | **Kargar Jahromi et al. (55); 2016; 30 versus 30; Tx=unclear, F/L=30 d** | Telenursing: 30-min telephone follow-up sessions 30 d after dialysis shift | TAU | DASS-21 depression subscale after intervention (mean [SD]): 8.96 (1.17) versus 16.20 (1.60); P=0.05 |
| | | | After intervention SDS: 36.48 (SD, 5.06) versus 48.80 (SD, 5.27); P<0.001 |
| | | | Both groups experienced significant decline in scores (P<0.001) |
| | | | NA |
| | **Li et al. (42); 2020; 36 versus 36; Tx=6 mo, F/L=6 mo** | Home nursing visits: care, guidance for patient and family, counseling, and dietary guidance | Telephone follow-up at 1, 3, and 6 mo after discharge | QoL (KDQOL-36): both groups experienced significant improvement (P<0.001); scores in Tx group higher than C (P<0.001) |
| | | | Poor |
| Author (Reference); Year; N | Randomized (T versus C); Duration of Treatment and Follow-Up | Treatment Comparator | Findings, Treatment versus Comparator | Quality |
|----------------------------|---------------------------------------------------------------|----------------------|-------------------------------------|---------|
| Liao et al. (43); 2020; 64 versus 64; Tx=unclear, during inpatient stay, F/U=3 mo | Comprehensive nursing: health education 1–2× per wk; CBT; progressive relaxation, extended f/u care | Conventional care | After intervention SDS: 51.02 (SD, 20.59) versus 60.06 (SD, 28.91); P=0.05 Improvement in scores from baseline: 9.81 (SD, 19.32) versus 3.96 (SD, 10.79); P=0.04 QoL (KDQOL-36) at 3-mo f/u: greater improvements from baseline for physical activity, mental state, burden of kidney disease, symptoms of kidney disease, and effects of kidney disease in T compared with C (all P<0.05) | Poor |
| Kalani et al. (39); 2019; 32 versus 32 versus 32; Tx=4 wk, F/U=4 wk | Acupressure: applied during first 2 h of HD; 3× per wk for 4 wk; each session lasted 20 min | Sham: same as acupressure group except pressure applied 1 cm from acupressure pointsControl: TAU | Post-test BDI-II: T 20.6 versus sham 25.5 versus C 24.9; significant difference T versus sham and C (P=0.001 for both); no difference between sham and C (P=0.22) Acupressure and TEAS are similarly effective, and significantly more effective than no intervention (P=0.009 and P=0.008, respectively); no difference between acupressure and TEAS (P=0.95) | Fair |
| Tsay et al. (48); 2014; 36 versus 36; Tx=4 wk, F/U=4 wk | Acupressure: applied for 15 min 3× per wk for 4 wk; TEAS: applied for 15 min 3× per wk for 4 wk | Control group (not described) | Fatigue (PFS): baseline T 5.92 (SD, 1.39) versus TEAS 5.60 (SD, 1.50) versus C 6.01 (SD, 1.60); follow-up T 4.61 (SD, 1.72) versus TEAS 4.70 (SD, 1.50) versus C 5.70 (SD, 1.80); post-hoc analysis found significantly lower levels in T (P=0.006) and TEAS (P=0.02) versus C. No difference between T and TEAS Sleep quality (PSQI): baseline T 8.85 (SD, 4.50) versus TEAS 7.12 (SD, 4.51) versus C 9.35 (SD, 3.48); follow-up T 7.80 (SD, 4.00) versus TEAS 6.32 (SD, 4.55) versus C 9.75 (SD, 4.65); compared with controls, significantly better with T (P=0.05) and TEAS (P=0.016); no difference between T and TEAS | Poor |
| Author (Reference); Year; N Randomized (T versus C); Duration of Treatment and Follow-Up | Treatment | Comparator | Findings, Treatment versus Comparator | Quality |
|---|---|---|---|---|
| **Exercise**<br>Frih et al. (34); 2017; 28 versus 22; Tx=4 mo, F/U=4 mo | Exercise (endurance-resistance) training: 60 min, 4× per wk on nondialysis days | Sedentary controls; no intervention | Favors exercise: T HADS depression scores were not different than C before intervention, but significantly lower than C after intervention ($P<0.01$). Within-group decrease also significant for T, but not C. Significant group × period interaction effect for HADS depression scores: $F_{(1, 39)}=43.91$, $P<0.001$ | Poor |
| Kouidi et al. (40); 2010; 25 versus 25; Tx=1 yr, F/U=1 yr | ET program (intradialytic): warm-up, cycling, strengthening, cooldown, 3× per wk, 60–90 min during first 2 h of HD session | Sedentary control | Favors ET in both BDI-II and HADS scores ($P<0.001$) | Poor |
| **Other interventions**<br>Babamohamadi et al. (28); 2017; 30 versus 30; Tx=1 mo, F/U=1 mo | Quran: listen to audio of Quran recitation on headphones for 20 min, beginning 5 min before dialysis | TAU | Post-test BDI-II scores: 14.5 (SD, 4.8) versus 31.6 (SD, 9.2); $P<0.001$ Significant between-subjects treatment effect, independent of age ($F=9.3$, $P=0.004$, Cohen d=0.85). | Poor |
| Author (Reference); Year; N Randomized (T versus C); Duration of Treatment and Follow-Up | Treatment | Comparator | Findings, Treatment versus Comparator | Quality |
|---|---|---|---|---|
| Beizaee et al. (29); 2018; 40 versus 40; Tx=4 wk; F/U=4 wk | Guided imagery: 3× per wk for 4 wk, in-person with psychologist; 30 mins before HD session; includes audio recording of nature sounds | TAU, nearly silent environment | Post-test HADS scores: 10.02 (SD, 2.58) versus 11.65 (SD, 2.33) | Fair |
| Depression Other outcomes | SBP: mean (SD) before, 129.22 (12.70) versus 132.85 (13.22); mean (SD) after, 121.75 (12.73) versus 134.87 (12.68) | DBP: mean (SD) before, 82.50 (11.32) versus 81.75 (8.51); mean (SD) after, 81.00 (10.32) versus 81.87 (8.14) | HR (SD): before, 77.95 (6.97) versus 75.42 (8.56); after, 73.75 (6.25) versus 77.22 (7.92) |
| Heshmatifar et al. (37); 2015; 35 versus 34; Tx=1 mo, F/U=1 mo | Benson relaxation technique: performed 20 min 2× per d for 1 mo | TAU | Only T group scores decreased; the difference between groups was significant (P=0.01) | Poor |
| Rahimipour et al. (45); 2015; 25 versus 25; Tx=8 wk, F/U=12 wk | Hope therapy: sessions using Schneider hope therapy theory, 1× per wk for 8 wk, 1–1.5 h during first 2 h of dialysis | Control: listening session in which patients could talk about their disease and problems, 1× per wk for 8 wk | Immediately after 8-wk intervention (t=12.75; P<0.001), and at 1-mo follow-up (t=13.83; P<0.001) | Poor |
| Thomas et al. (47); 2017; 21 versus 20; Tx=8 wk, F/U=8 wk | MBSR*: guided, chairside meditative practices, 10–15 min, 3× per wk during hemodialysis sessions | TAU* | Change in PHQ-9: –3.0 (SD, 3.9) versus 2.0 (SD, 4.7); P=0.45 | Fair |
| Widyaningrum and Djarwoto (51); 2013; 18 versus 18; Tx=3 wk, F/U=3 wk | LPD relaxation technique and repetitive prayer practice, 2× per d for 21 d | Control group (not described) | Significantly decreased BDI-II scores within both groups, and greater in LPD, but between group difference NS (P=0.20) | Poor |

T, treatment group; C, control group; SSRIs, selective serotonin reuptake inhibitors; Tx, treatment; F/U, follow-up; BDI-II, Beck Depression Inventory-II; BSI, Brief Symptom Inventory; HAM-D, Hamilton Depression Rating Scale; MADRS, Montgomery–Åsberg Depression Rating Scale; VAS, Visual Analogue Scale; NA, not applicable; Δ, change; HADS, Hospital Anxiety and Depression Scale; AE, adverse event; CBT, cognitive behavioral therapy; HD, hemodialysis; QIDS-C, Quick Inventory of Depressive Symptomatology–Clinician; L. acidophilus, Lactobacillus acidophilus; B. bifidum, Bifidobacterium bifidum; FOS, fructo-oligosaccharides; GOS, galacto-oligosaccharides; HADS-D, Hospital Anxiety and Depression Scale–Depression; QoL, quality of life; PSE, psychoeducation; MINI, Mini International Neuropsychiatric Interview; KDQOL, Kidney Disease Quality of Life; RR, relative risk; PLC, Profile of Quality of Life in the Chronically Ill; DASS-21, 21-Item Depression, Anxiety, and Stress Scale; SDS, Self-Rating Depression Scale; SE.standard error; TEAS, transcutaneous electrical acupoint stimulation; PFS, Piper Fatigue Scale; PSQI, Pittsburgh Sleep Quality Index; SF-36, 36-Item Short Form Health Survey; PCS, Physical Component Scale; MCS, Mental Component Scale; ET, exercise training; MSSD, mean squared successive difference; SBP, systolic BP; DBP, diastolic BP; HR, heart rate; MBSR, mindfulness-based stress reduction; PHQ-9, Patient Health Questionnaire-9; LPD, Latihan Pasrah Diri. *Both treatment and control groups also received psychoeducational literature on anxiety and depression.
| Outcome | Conclusion | Strength of Evidence (Justification)* |
|---------|------------|--------------------------------------|
| **Pharmacologic** | | |
| SSRIs versus controls (k=3; n=94) | Depression severity<br>Fluoxetine (30)<br>No benefit (k=1; n=14)<br>Sertraline (33,46)<br>Mixed findings (k=2; n=80) | Insufficient (NC, SLM) |
| SSRIs versus active comparator (k=2; n=164) | Depression severity<br>Sertraline versus CBT (44)<br>Benefit for both; no difference between groups (k=1, n=120)<br>Citalopram versus psychologic training (38)<br>Benefit for both; no difference between groups (k=1, n=44) | Low (SLM, UC) |
| Supplements versus placebo (k=4; n=986) | Depression severity<br>Ω-3 Fatty acids (35)<br>Increased benefit (k=1, n=54)<br>High-dose vitamin D3 (50)<br>No benefit (k=1, n=746)<br>Symbiotic or probiotic (36)<br>Increased benefit (k=1, n=49)<br>Radix Bupleuri (49)b<br>Increased benefit (k=1, n=137)<br>Radix Bupleuri (49)b<br>Increased benefit (k=1, n=137) | Insufficient (NP, SLH, UC) |
| Nonpharmacologic | | |
| CBT versus active comparator (k=2; n=220) | Depression severity<br>CBT versus psychoeducation (27)<br>Benefit for both, but favored psychoeducation (k=1, n=130)<br>CBT versus psychotherapy (32)<br>Benefit for both, but favored CBT (k=1, n=90) | Insufficient (SLH, UC) |
| Suicide risk | CBT versus psychotherapy (32)<br>Benefit in intervention but not control group; no difference between groups (k=1, n=90) | Low (SLM, UC) |
| QoL | CBT versus psychotherapy (32)<br>Increased benefit for some domains of KDQOL (k=1, n=90) | Insufficient (SLM, UC) |
| CBT versus control (k=2; n=125) | Depression severity<br>Increased benefit (k=2; n=125) (31,41)<br>Low (SLM) |
| QoL | Increased benefit (k=2; n=125) (31,41)<br>Low (SLM) |
| Fluid adherence | Increased benefit (k=1; n=65) (31) | Insufficient (SLM, UC) |
| Acupressure versus control (k=2; n=204) | Depression severity<br>Acupressure versus TAU (39,48)<br>Increased benefit (k=2; n=204)<br>Acupressure versus sham (39)<br>Increased benefit (k=1; n=96) | Low (SLM) |
| Fatigue | Acupressure versus TAU (48)<br>Increased benefit (k=1, n=108) | Insufficient (SLH, UC) |
| Sleep quality | Acupressure versus TAU (48)<br>Increased benefit (k=1, n=108) | Insufficient (SLH, UC) |
| Acupressure versus active comparator (k=1, n=108) (48) | Depression severity<br>Acupressure versus TEAS<br>Benefit for both; no difference between groups | Insufficient (SLH, UC) |
| Fatigue | Acupressure versus TEAS<br>Benefit for both; no difference between groups | Insufficient (SLH, UC) |
| Sleep quality | Acupressure versus TEAS<br>Benefit for both; no difference between groups | Insufficient (SLH, UC) |
| Nursing interventions: intensive versus less-intensive nursing (k=3; n=260) | Depression severity<br>Increased benefit (k=3; n=260) (42,43,55) | Insufficient (SLH, NP) |
| QoL | Increased benefit (k=2; n=200) (42,43) | Insufficient (SLH, NP) |
| Benson relaxation technique versus control (k=1; n=70) (37) | Depression severity<br>Increased benefit | Insufficient (SLH, UC) |
Supplements versus Placebo

**High-dose Vitamin D3.** A large (N=746), fair-quality, 52-week RCT (50) provides moderate-strength evidence that long-term, high-dose vitamin D3 does not reduce depression severity in adults with ESKD (Tables 3 and 4). In addition, no differences were reported by age, sex, body mass index, or plasma albumin level. Although overall differences in depressive-symptom reduction between groups were NS, a subgroup of participants with vascular depression (but not those with major depressive disorder) receiving vitamin D3 did report significantly greater reduction in depressive symptoms at 1 year (Table 2).

**Harms of Vitamin D3.** AEIs associated with high-dose vitamin D3, including joint pain, diarrhea, nausea, and vomiting, resulted in study withdrawal of five participants. No statistical analyses of AEs or withdrawals due to AEs were reported (50).

**Ω-3 Fatty Acids.** A single, poor-quality RCT (N=54) (35), conducted in Iran, provides insufficient evidence to form conclusions about the effect of Ω-3 fatty acids versus placebo on depression severity in adults with ESKD (Tables 3 and 4). At 16 weeks, the Ω-3 fatty acids group reported a significantly greater reduction in depressive symptoms compared with both placebo and their own baseline. No differences were identified by age, sex, baseline depression severity, or length of time on hemodialysis (Table 2). No serious AEs (SAEs) were reported in this trial.

**Synbiotic and Probiotic Supplements.** One good-quality, 12-week RCT (N=49) (36) provides insufficient evidence for the use of synbiotic or probiotic supplements versus placebo on depression severity in Iranian adults with ESKD and Hospital Anxiety and Depression Scale–Depression (HADS-D) scores of eight or higher (Tables 3 and 4). HADS-D scores at the end of treatment were significantly lower in adults receiving synbiotics than those receiving placebo (P<0.001) and probiotics (P=0.01). HADS-D scores were also significantly reduced from baseline in the synbiotic compared with placebo (P<0.001) groups, but not in the other comparisons (Table 2). The reported AEs were few and mild (Table 5).

**Radix Bupleuri Herbal Supplement.** A poor-quality, 3-month RCT (N=160) (49) of Radix Bupleuri root powder supplements compared with placebo provides insufficient evidence for its use for depression in adults with ESKD (Tables 3 and 4). Participants who were being treated with antidepressant medications (about half of each group) continued on those treatments concurrently during this trial. Participants taking Radix Bupleuri experienced significantly more reduction in Montgomery–Åsberg Depression Rating Scale scores compared with the placebo group (P<0.02; Table 2). They also experienced improvement in QoL (measured by RAND-36) compared with the placebo group (P=0.04). The trial did not report on AEs.

**Nonpharmacologic Treatments**

**CBT**

**CBT versus Psychotherapy.** One fair-quality RCT (N=90) (32) provides low-strength evidence that small-group CBT is more effective than brief, individualized psychotherapy for reducing depression severity in participants with ESKD (Tables 3 and 4). Depressive symptoms improved significantly in both groups. Participants receiving CBT also experienced a significant within-group decrease in suicide risk and improved on several QoL domains (i.e., burden of...
Table 4. Quality and applicability assessment of randomized controlled trials

| Author (Reference) | Rating Criteriaa | Funding source | Overall Quality | Applicability |
|--------------------|------------------|----------------|----------------|--------------|
| Al Saraireh et al. (27) | Y NR N NA Y U U N Y N Y N Y U Y NA N | Investigator | Poor | Fair |
| Babamohamadi et al. (28) | NR NR N U Y U U N Y N U N Y U U N | NR | Poor | Poor |
| Beizaee et al. (29) | Y Y Y Y Y Y N Y N Y N U Y NA Y | University | Fair | Fair |
| Blumenthal et al. (30) | NR Y U U N U Y Y Y U Y U N | Industry grant | Poor | Fair |
| Cukor et al. (31) | NR NR Y U Y Y Y Y N Y N U U N | NIDDK | Fair | Fair |
| Duarte et al. (32) | Y Y N U Y Y Y Y Y N Y U Y N | Government | Fair | Fair |
| Friedli et al. (33) | Y Y N Y Y Y Y Y N Y U U N | NIH grant | Fair | Good |
| Frith et al. (34) | Y NR U Y Y Y N N Y U Y U U N | NR | Poor | Fair |
| Gharakani et al. (35) | Y U Y N Y N Y Y Y Y N Y N | University | Poor | Good |
| Haghighat et al. (36) | Y Y Y U Y Y Y Y Y Y Y Y U N | Ahvaz Jundishapur Univ Med Sci | Good | Fair |
| Heshmatifar et al. (37) | NR NR Y U U U N Y N N Y N U U N | NR | Poor | Fair |
| Hosseini et al. (38) | U NR Y Y Y U U N Y N N Y Y U Y N | Government | Poor | Fair |
| Jahromi et al. | NR NR Y Y Y Y Y N U N Y N U N | NR | Poor | Fair |
| Kalani et al. (39) | N U Y U Y U U U Y U Y N Y Y Y U | University | Poor | Fair |
| Kouidi et al. (40) | NR Y U U U U N Y N N Y Y U U N | NR | Poor | Fair |
| Lerman et al. (41) | Y NR Y U Y Y Y N N N N U U N | NR | Poor | Fair |
| Li et al. (42) | Y N Y Y Y N N N U U U Y U U | NR | Poor | Fair |
| Liao et al. (43) | Y NR Y Y Y U U U Y N N Y U Y N | NR | Poor | Fair |
| Mehrotra et al. (44) | Y Y U Y Y Y N N Y N Y N U N | Government, University, NIDDK, DCI | Fair | Fair |
| Rahimpour et al. (45) | U NR U Y U U U U N U U U U U U | NR | Poor | Fair |
| Taraz et al. (46) | Y U Y Y Y U U Y Y N N N Y Y Y N | University grant | Fair | Good |
| Thomas et al. (47) | Y NR U Y U U U Y U Y N N Y Y Y U | University grant | Fair | Fair |
| Tsay et al. (48) | NR NR Y U Y U U U Y N N Y Y U Y N | Government | Poor | Fair |
| Wang et al. (49) | NR NR Y N Y U U U Y Y Y N U U N | NR | Poor | Fair |
| Wang et al. (50) | Y Y Y U Y U U U Y N N U Y Y Y N | NR | Fair | Poor |
| Widyaningrum et al. (51) | NR NR Y U U U U U U U U U U U | NR | Poor | Poor |

Y, yes; NR, not reported; N, no; NA, not applicable; U, unclear; NIDDK, National Institute of Diabetes and Digestive and Kidney Diseases; NIH, National Institutes of Health; Univ Med Sci, University of Medical Sciences; DCI, Dialysis Clinic Inc.

aThe quality rating criteria (adapted from the US Preventive Services Task Force criteria [26]) involved evaluating the following questions:
1. randomization adequate?
2. allocation concealment adequate?
3. groups similar at baseline?
4. maintain comparable groups?
5. eligibility criteria specified?
6. outcome assessors masked?
7. care provider masked?
8. patient masked?
9. reporting of attrition, crossovers, adherence, and contamination?
10. important differential loss to follow-up or overall high loss to follow-up?
11. intention-to-treat analysis?
12. postrandomization exclusions?
13. outcomes prespecified and defined, and ascertained using accurate methods?
14. intervention fidelity?
15. follow-up long enough for outcomes to occur? (minimum 4 wk for drugs)
16. appropriate handling of missing data?
17. evidence of selective outcome reporting?
Table 5. Adverse events reported in depression treatment trials in patients with ESKD

| Severity     | System     | Adverse Event          | Blumenfield et al. (30) | Friedli et al. (33)* | Haghighat et al. (36) | Mehrotra et al. (44) | Taraz et al. (46)b |
|--------------|------------|------------------------|-------------------------|----------------------|----------------------|----------------------|-------------------|
|              |            |                        | FLU (N=6)                | PBO (N=7)            | SERT (N=15)          | PBO (N=15)           | Probiotic (N=25)  | PBO (N=25)       |
|              |            |                        | CBT (N=60)               | SERT (N=60)          | SERT (N=21)          | SERT (N=22)          |                   |                   |
| Nonserious   | Autonomic  | Dry mouth              | 0                       | 1                    | —                    | —                    | 3                 | 9                |
| Cardiovascular |          | Cardiac unspecified   | —                       | —                    | —                    | —                    | —                 | —                |
|              |            | Hypotension            | 4                       | 1                    | 1                    | 0*                   | 3                 | 1                |
| Gastrointestinal |         | Palpitations           | —                       | —                    | —                    | —                    | —                 | —                |
|              | Abdominal pain |                | 1                       | 2                    | —                    | —                    | —                 | —                |
|              | Constipation |                    | 0                       | 1                    | —                    | —                    | —                 | —                |
|              | Diarrhea    |                        | 1                       | 1                    | —                    | —                    | —                 | —                |
|              | Dyspepsia   |                        | 1                       | 0                    | —                    | —                    | —                 | —                |
|              | Gastroenteritis |                | 0                       | 2                    | —                    | —                    | —                 | —                |
|              | Gastrointestinal unspecified |           | —                       | —                    | —                    | —                    | —                 | —                |
| Musculoskeletal |          | Nausea                 | 5                       | 2                    | 1                    | 0*                   | 7                 | 3                |
| Neurologic   | Myalgia     |                        | 3                       | 3                    | —                    | —                    | —                 | —                |
|              | Dizziness   |                        | 1                       | 1                    | 0*                   | 0*                   | —                 | —                |
|              | Headache    |                        | 3                       | 0                    | 1                    | 0*                   | 5                 | 3                |
|              | Insomnia    |                        | 2                       | 1                    | 1                    | 0*                   | 4                 | 2                |
|              | Nervous system unspecified |          | —                       | —                    | —                    | —                    | —                 | —                |
|              | Sensation disturbance |          | 1                       | 0                    | —                    | —                    | —                 | —                |
|              | Tremors     |                        | 1                       | 0                    | —                    | —                    | —                 | —                |
| Psychiatric  | Abnormal thought |              | 1                       | 0                    | —                    | —                    | —                 | —                |
|              | Anorexia    |                        | —                       | —                    | —                    | —                    | —                 | —                |
|              | Anxiety     |                        | 0                       | 1                    | —                    | —                    | —                 | —                |
| Respiratory  | Nervousness |                        | 1                       | 1                    | —                    | —                    | —                 | —                |
|              | Bronchitis  |                        | 1                       | 0                    | —                    | —                    | —                 | —                |
|              | Cough       |                        | 0                       | 2                    | —                    | —                    | —                 | —                |
|              | Dyspnea     |                        | 1                       | 0                    | —                    | —                    | —                 | —                |
|              | Pharyngitis |                        | 1                       | 0                    | —                    | —                    | —                 | —                |
|              | Rhinitis    |                        | 1                       | 0                    | —                    | —                    | —                 | —                |
|              | Upper respiratory tract infection |    | 1                       | 0                    | —                    | —                    | —                 | —                |
| Skin         | Furunculosis |                    | 1                       | 0                    | —                    | —                    | —                 | —                |
|              | Pruritus    |                        | 1                       | 0                    | —                    | —                    | —                 | —                |
|              | Skin ulcer  |                        | 0                       | 1                    | —                    | —                    | —                 | —                |
|              | Sweating    |                        | —                       | —                    | 1                    | 0*                   | —                 | —                |
| Other        | Dehydration |                        | 0                       | 1                    | —                    | —                    | —                 | —                |
|              | Edema       |                        | 0                       | 1                    | —                    | —                    | —                 | —                |
|              | Fatigue     |                        | —                       | —                    | 1                    | —                    | —                 | —                |
|              | Flu syndrome |                    | 1                       | 0                    | —                    | —                    | —                 | —                |
|              | Hair loss   |                        | —                       | —                    | —                    | —                    | 3                 | 17               |
|              | Other unspecified |              | —                       | —                    | —                    | —                    | 2                 | 1                |
|              | Sexual dysfunction |            | —                       | —                    | —                    | —                    | —                 | —                |
|              | Tooth infection |                | 1                       | 0                    | —                    | —                    | —                 | —                |
| Severity | System          | Adverse Event                | Blumenfield et al. (30) | Friedli et al. (33)* | Haghighat et al. (36) | Mehrotra et al. (44) | Taraz et al. (46)* |
|----------|----------------|-------------------------------|-------------------------|----------------------|----------------------|----------------------|-------------------|
|          |                |                               | FLU (N=6)               | PBO (N=7)            | SERT (N=15)          | PBO (N=15)          | Probiotic (N=25)   | PBO (N=25)        | CBT (N=60)   | SERT (N=60) | SERT (N=21) | PBO (N=22) |
| Severe   | Gastrointestinal | Gastrointestinal unspecified  | —                       | —                    | —                    | —                    | 1                 | 1                | —            | —            | —            | —            |
|          | Cardiovascular  | Cardiac unspecified          | —                       | —                    | 1                    | 0                    | 2                 | 0                | —            | —            | —            | —            |
|          | Other           | Death                         | —                       | —                    | —                    | —                    | 1                 | 2                | —            | —            | —            | —            |
|          | Other unspecified | Major bleeding                | —                       | —                    | —                    | —                    | 2                 | 2                | —            | —            | —            | —            |
|          | Other unspecified | Other unspecified             | —                       | —                    | —                    | —                    | 2                 | 9                | —            | —            | —            | —            |

FLU, fluoxetine; PBO, placebo; SERT, sertraline; CBT, cognitive behavioral therapy.

*The events reported in this table are only those that resulted in study dropout. There were other adverse events reported narratively, but it was not clear from the text in which category or study arm they occurred, so they are not recorded in this table.

*It is unclear whether the events of study dropouts were included in these totals. There was one death in each group and some attrition due to adverse events, but the dropouts were not analyzed in this per-protocol study.
### Table 6. Adverse events reported in observational studies of adults with ESKD and depression

| Author (Reference); N; Years; Source | Treatment versus Comparator | Outcomes of Interest | Findings |
|--------------------------------------|----------------------------|----------------------|----------|
| Assimon et al. (57); N=65,654; 2007–2014; Medicare Recipients in the US Renal Data System Database | SSRIs with higher QT-prolonging potential \(^a\) versus SSRIs with lower QT-prolonging potential \(^b\) | 1-yr sudden cardiac death | Compared to SSRIs with lower QT-prolonging potential, those with higher QT-prolonging potential were associated with higher risk of sudden cardiac death (AHR, 1.18; 95% CI, 1.05 to 1.31); this association was more pronounced among older adults (AHR, 1.19; 95% CI, 1.05 to 1.35), women (AHR, 1.23; 95% CI, 1.06 to 1.44), patients with conduction disorders (AHR, 1.47; 95% CI, 1.05 to 2.06), and those treated with other non-SSRI QT-prolonging medications (AHR, 1.29; 95% CI, 1.10 to 1.50) |
| Guirguis et al. (56); N=41; 2013–2015; ASSertID Study | Antidepressants (no comparator) | Antidepressant-management practices related to NICE guidelines | At baseline, 30 patients had BDI-II scores ≥16, and 22 remained high at follow-up; At baseline, 11 patients had BDI-II scores <16; five of 11 were ≥16 on follow-up; 27 of the 41 patients (66%) either deteriorated or failed to improve; 16 patients (39%) had no review of antidepressant medication; a significant proportion of patients were taking agents cautioned against, or with no available prescribing information in, for patients on HD, or they were taking doses that might be considered subtherapeutic; 15% had no evidence of ever having had MDD over their lifetime according to the MINI, in spite of their being on antidepressants |
| Author (Reference); N; Years; Source | Treatment versus Comparator | Outcomes of Interest | Findings |
|--------------------------------------|-----------------------------|-----------------------|----------|
| Vangala et al. (58); N=54,032; 2009–2015; Medicare Recipients in the US Renal Data System Database | SSRI versus no SSRI | Hip fracture | Any SSRI use was associated with increased hip fracture risk (AOR, 1.25; 95% CI, 1.17 to 1.35); risk for fracture was estimated for low (AOR, 1.20; 95% CI, 1.08 to 1.32), moderate (AOR, 1.31; 95% CI, 1.18 to 1.43), and high SSRI use (AOR, 1.26; 95% CI, 1.12 to 1.41); the relationship between hip fracture events and SSRI use was also seen in the examination of new short-term use (AOR, 1.43; 95% CI, 1.23 to 1.67); no significant interaction with age, sex, BMI, race, or ethnicity was discovered in the short-term analysis |

SSRIs, selective serotonin reuptake inhibitors; AHR, adjusted hazard ratio; ASSertID, A Study of Sertraline in Dialysis; NICE, National Institute for Health and Care Excellence; BDI-II, Beck Depression Inventory-II; HD, hemodialysis; MDD, major depressive disorder; MINI, Mini International Neuropsychiatric Interview; AOR, adjusted odds ratio; BMI, body mass index.

*Citalopram and escitalopram.

*Fluoxetine, fluvoxamine, paroxetine, and sertraline.
kidney disease, quality of social interaction, sleep, overall health, and mental health) over the study period (Table 2). No study dropouts from serious AEs were reported.

CBT versus Psychoeducation. A poor-quality RCT (27), conducted in Jordan, provides insufficient evidence to form conclusions about the comparison of CBT with psychoeducation (Tables 3 and 4). Participants receiving CBT reported a significantly greater reduction in depressive symptoms (both groups reported significant improvement; Table 2).

CBT versus Sertraline. A head-to-head RCT (44) provides low-strength evidence that sertraline and CBT are similar when used for the reduction of depressive symptoms in participants with depression and ESKD. See the section SSRIs versus CBT above and Tables 2-4 for more detail.

CBT versus Control. Two fair-quality RCTs (31,41) provide low-strength evidence that CBT is more effective than wait-list control for reducing depression severity and improving QoL in participants with ESKD (Tables 3 and 4). There is insufficient evidence to form conclusions about the benefit of CBT on fluid adherence (31).

One study compared outcomes (depressive symptoms, QoL, and fluid adherence) on the basis of the timing of the intervention (treatment first or after 90-day wait listing). Results indicated that participants receiving CBT experienced significantly greater benefit across all outcomes in both phases. However, findings suggest a sequence effect for depressive-symptom reduction (the treatment-first group experienced greater benefit than the wait-list group), but none for QoL or fluid compliance (Table 2) (31).

Acupressure
We found low-strength evidence that acupressure is more effective than both usual care and sham acupressure for reducing depression severity in participants with ESKD (Table 3). There is insufficient evidence to form conclusions about the comparison of acupressure to transcutaneous electrical acupoint stimulation (TEAS) for the reduction of depressive-symptom severity, fatigue, or sleep-quality improvement. A fair-quality, three-arm RCT (N=96) (39) compared acupressure with sham acupressure (i.e., pressure applied 1 cm from the acupressure point) and usual care. Participants receiving acupressure reported a significantly greater reduction in depression symptoms than those receiving sham acupressure or usual care (there was no difference between sham and usual care). A second three-arm RCT (poor quality; N=108) (48) compared acupressure with both TEAS and usual care. Participants in both the acupressure and the TEAS groups reported greater reductions in depressive symptoms and fatigue, and better-quality sleep than those who received usual care (Tables 2 and 4).

Intensive Nursing
Three poor-quality RCTs (42,43,55) provide insufficient evidence for the effect of intensive nursing interventions, compared with less-intensive nursing, for improving depressive symptoms in adults with ESKD (Tables 3 and 4). One study in China (N=72) compared home-nursing visits with telephone follow-up for adults on peritoneal dialysis (42). Although both groups’ Zung Self-Rating Depression Scale scores were improved from baseline (P<0.001), the home-nursing group’s depression scores were significantly lower than the control group after intervention (P<0.001). Another Chinese study of a comprehensive nursing intervention compared with usual care (N=128) (43) in adults on hemodialysis found that the intervention group had significantly greater reduction in Self-Rating Depression Scale scores from baseline (P=0.04), and those scores were significantly better after intervention compared with the control group (P=0.05). An Iranian RCT (N=60) using the Depression, Anxiety, and Stress Scale found that teleduring follow-ups compared with usual care (no telephone follow-ups) resulted in significantly lower depression scores (Table 2) (55). These studies did not report on AEs.

Exercise
There was insufficient evidence from two poor-quality studies (34,40) on exercise training for depression in adults with ESKD (Tables 3 and 4). One study (N=50) (34) examined the effect of 4 months of endurance and resistance training four times weekly in Tunisian male participants. Training sessions were on off-dialysis days and the exercise group significantly improved on HADS-D scores compared with sedentary controls. The other, a Greek RCT (N=50) (40), examined intradialytic exercise (during hemodialysis cycling and strength training) three times per week for a year and found significant improvement on both the Beck Depression Inventory-II and HADS-D with exercise compared with sedentary controls (Table 2). AEs were not reported.

Other Treatments
We included RCTs of six other therapies: Benson relaxation technique (37), guided imagery (29), hope therapy (45), Latihan Pasrah Diri (51), mindfulness-based stress reduction (47), and Quran readings for Muslim participants (28). All were small, single trials with methodologic challenges, and the evidence is insufficient for all interventions (Tables 2-4). Two of these studies (Latihan Pasrah Diri [51] and mindfulness-based stress reduction [47]) reported no AEs, whereas the others did not report on AEs.

Discussion
In this systematic review, we examined nine RCTs of pharmacologic interventions and 17 of nonpharmacologic interventions for comorbid depression in adults with ESKD. We also found three observational studies that contributed to the evidence on harms of SSRIs. We found moderate-strength evidence that long-term, high-dose vitamin D3 is ineffective for reducing depressive symptoms, and low-strength evidence that both sertraline and CBT were similar for improving depressive symptoms. We also found low-strength evidence that CBT is more effective than both standard psychotherapy and wait-list controls, and that acupressure is more effective than usual care. We found insufficient evidence to draw conclusions about all other interventions. Overall, we found limited evidence for each intervention, sample sizes were small, and nearly all studies were hampered by methodologic flaws.

KIDNEY360 2: 558–585, March, 2021 Depression Treatment for Adults with ESKD, Chopra et al. 581
SSRIs, compared either with placebo or an active comparator, were the best-studied pharmacologic intervention. No other antidepressant categories were identified. Findings from placebo-controlled trials of SSRIs were mixed, but sertraline at least warrants further study. Among the three trials examining sertraline, one reported benefit over placebo, and another found no difference between sertraline and CBT (44). Harms related to SSRIs were not uniformly reported. The type and rate of harms reported and/or evaluated in included RCTs suggest little to no increase in risk for adults with ESKD compared with otherwise healthy adults using SSRIs. Primary side effects were minor (e.g., nausea, fatigue). However, observational studies suggest that clinicians should consider known risks (e.g., QT prolongation) when making prescribing decisions, and to coordinate care to avoid over- or undertreatment.

Vitamin D3 is an interesting intervention for adults with ESKD, due to the associated risks of hypercalcemia and hyperphosphatemia (60). Five adults withdrew from the study due to treatment-related AEs. Although not attributed to hyperphosphatemia, the reported AEs (i.e., joint pain, diarrhea, nausea, and vomiting) may be related. The negative finding regarding vitamin D3, along with its risks, suggests that clinicians should not recommend its use as a depression treatment in this population. Given the large size and length of the trial, the SOE for this finding is moderate, and future studies are unlikely to change conclusions.

Very few nonpharmacologic studies reported harms; however, most interventions presented minimal risk. Differences by subpopulation (i.e., demographic, clinical) were also reported in very few studies, and reported differences were insufficient to form conclusions. Future research should uniformly report harms and examine these subgroups.

Many of the studies were hampered by small sample sizes, posing challenges related to group comparability and statistical power. The duration of treatment and follow-up varied widely across studies, making it more challenging to compare results. For instance, between two studies of sertraline, one was twice as long as the other (3 versus 6 months). The methods used to screen for and diagnose depression were heterogeneous, as was the implementation of interventions (e.g., timing, doses, comparators, modes of delivery). For example, among CBT studies, although all of them met in person, half of the studies used private sessions, and sessions were conducted in groups in the other studies. Session lengths varied and, in one study, CBT was delivered while the participants were receiving hemodialysis. Given the association with hemodialysis and somatic complaints, hemodynamic changes, and alterations in mental acuity, treatments (particularly psychologic ones) that are administered during hemodialysis may be confronted with these challenges; although treating adults outside of hemodialysis sessions has its own challenges, including the increased time burden and physical and mental fatigue. Among other psychologic treatments, some were applied in person, whereas others were practices expected to be followed at home. In addition to these issues, the lack of methodologic detail reported in many of the studies resulted in poor-quality ratings and uncertainty about study processes.

Another important limitation to the current evidence base is that most of the studies were conducted outside of the United States and examined participants and health systems that differ greatly from the general US population. These differences may be reflected in both the patient demographics and medical disease burden, and in how care is delivered, particularly because the majority of US adults on dialysis receive their care from large dialysis organizations in coordination with their nephrology provider.

This is the only systematic review to date that examines both pharmacologic and nonpharmacologic treatment of depression in adults with ESKD. This review confirms and adds to a 2016 Cochrane review of antidepressants in adults with ESKD, which included meta-analyses of harms reported in trials included in our report (59). Although we also included more recent trials, outcomes were not reported in a way that allowed for a quantitative synthesis of harms. Our review adds to the pharmacologic evidence by including studies of dietary supplements. A Cochrane review examining psychosocial interventions for adults with ESKD was recently published (61); however, it includes studies of participants with and without clinical depression. How a participant with ESKD responds to an intervention may vary widely depending on the severity of their baseline depressive symptoms. To reduce clinical heterogeneity, we included only studies with participants meeting established depression-screening thresholds for chronically ill populations (19–23). Finally, additional trials included in our review, particularly the ASCEND (44) and ASsertID trials (33,44), add to both the pharmacologic and nonpharmacologic evidence.

Future research, particularly in the United States, is needed to better evaluate both pharmacologic and nonpharmacologic interventions for this population. In particular, larger replication studies of CBT, acupressure, and SSRIs (such as sertraline), and examination of their effects in different subgroups of adults with ESKD and depression (such as severity of depression, duration of ESKD diagnosis, peritoneal versus hemodialysis, and presence of comorbidities), will help decision makers to implement depression treatments that are not only evidence based, but are also the best fit for their patient population.

Disclosures
All authors have nothing to disclose.

Funding
This research was funded by the US Department of Veterans Affairs, VHA, Office of Research and Development, Health Services Research and Development.

Acknowledgments
The authors wish to thank Ms. Robin Paynter (MLIS) for developing the search strategy and running electronic searches. We also thank the members of our technical expert panel for their expertise.

The findings and conclusions in this document are those of the authors who are responsible for its contents; the findings and conclusions do not necessarily represent the views of the Department of Veterans Affairs or the US Government.
Each author contributed important intellectual content during manuscript drafting or revision, accepts personal accountability for the author’s own contributions, and agrees to ensure that questions pertaining to the accuracy or integrity of any portion of the work are appropriately investigated and resolved.

Author Contributions
J.R. Antick, D. Kansagara, and K. Kondo provided supervision; C.K. Ayers was responsible for project administration; C.K. Ayers, P. Chopra, D. Kansagara, and K. Kondo reviewed and edited the manuscript; C.K. Ayers, P. Chopra, and K. Kondo were responsible for investigation; C.K. Ayers and K. Kondo were responsible for data curation and methodology; and all authors conceptualized the study, were responsible for formal analysis, and wrote the original draft.

Supplemental Material
This article contains supplemental material online at http://kidney360.asnjournals.org/lookup/suppl/doi:10.34067/KID.0003142020/-/DCSupplemental.
Supplemental Appendix 1. Search strategies (parent VA review).
Supplemental Appendix 2. Study selection criteria (parent VA review).
Supplemental Table 1. PICOTS by key question.
Supplemental Table 2. Strength of evidence domains and grading.

References
1. United States Renal Data System, USRDS Annual Data Report United States Renal Data System 2018 Available at: https://www.usrds.org/media/2283/2018_volume_2_esrd_in_the_us.pdf. Accessed April 20, 2019.
2. Fukunishi I, Kitaoa T, Shirai T, Kino K, Kanematsu E, Sato Y: Psychiatric disorders among patients undergoing hemodialysis therapy. Nephron 91: 344–347, 2002 https://doi.org/10.1159/000058418.
3. Kimmel PL, Thamer M, Richard CM, Ray NF: Psychiatric illness in patients with end-stage renal disease. Am J Med 105: 214–221, 1998 https://doi.org/10.1016/S0002-9343(98)00245-9.
4. De Sousa A: Psychiatric issues in renal failure and dialysis. Indian J Nephrol 18: 47–50, 2008 https://doi.org/10.4103/0971-4065.2337.
5. National Institute of Mental Health: Major depression. Available at: https://www.nimh.nih.gov/health/statistics/major-depression.shtml. Accessed October 31, 2019.
6. Palmer S, Vecchio M, Craig JC, Tonelli M, Johnson DW, Niccolucci A, Pellegrini F, Saglimbene V, Logroscino G, Fishbane S, Strippoli GF: Prevalence of depression in chronic kidney disease: Systematic review and meta-analysis of observational studies. Kidney Int 84: 179–191, 2013 https://doi.org/10.1038/ki.2013.77.
7. Lacson E Jr, Bruce L, Li NC, Mooney A, Maddux FW: Depressive affect and hospitalization risk in incident hemodialysis patients. Clin J Am Soc Nephrol 9: 1713–1719, 2014 https://doi.org/10.2215/CJN.01340214.
8. Farrokhi F, Abedi N, Beyene J, Kurdyak P, Jassal V: Association between depression and mortality in patients receiving long-term dialysis: A systematic review and meta-analysis. Am J Kidney Dis 63: 623–635, 2014 https://doi.org/10.1053/j.ajkd.2013.08.024.
9. Xing L, Chen R, Diao Y, Qian J, You C, Jiang X: Do psychological interventions reduce depression in hemodialysis patients? A meta-analysis of randomized controlled trials following PRISMA. Medicine (Baltimore) 95: e4675, 2016 https://doi.org/10.1097/MD.0000000000004675.
10. Weisbord SD, Mor MK, Sevick MA, Shields AM, Rollman BL, Palevsky PM, Arnold RA, Green JA, Fine MJ: Associations of depressive symptoms and pain with dialysis adherence, health resource utilization, and mortality in patients receiving chronic hemodialysis. Clin J Am Soc Nephrol 9: 1594–1602, 2014 https://doi.org/10.2215/CJN.00220114.
11. Kurella M, Kimmel PL, Young BS, Chertow GM: Suicide in the United States end-stage renal disease program. J Am Soc Nephrol 16: 774–781, 2005 https://doi.org/10.1681/ASN.2004070550.
12. Watnick S, Kirwin P, Mahnensmith R, Concato J: The prevalence and treatment of depression among patients starting dialysis. Am J Kidney Dis 41: 105–110, 2003 https://doi.org/10.1016/j.ajkd.2003.30029.
13. Kimmel PL, Peterson RA, Weisb KL, Simmons SJ, Alleyne S, Cruz I, Veis JH: Psychosocial factors, behavioral compliance and survival in urban hemodialysis patients. Kidney Int 54: 245–254, 1998 https://doi.org/10.1046/j.1523-1755.1998.00899.x.
14. Sullivan JE, Choi NG, Vazquez CE, Neaves MA: Psychosocial depression interventions for dialysis patients, with attention to Latinos: A scoping review. Res Soc Work Pract 29: 910–923, 2019 https://doi.org/10.1177/1049731518820134.
15. Shirazian S, Grant CD, Aina O, Mattana J, Khorasan F, Ricoard AC: Depression in chronic kidney disease and end-stage renal disease: Similarities and differences in diagnosis, epidemiology, and management. Kidney Int Rep 2: 94–107, 2016 https://doi.org/10.1016/j.ekir.2016.09.005.
16. Kondo K, Ayers CK, Chopra P, Antick J, Kansagara D: End Stage Renal Disease and Depression: A Systematic Review: VA ESP Project 405-225. Washington, DC: Evidence Synthesis Program, Health Services Research and Development Service, Office of Research and Development, Department of Veterans Affairs, 2020. Available at: https://www.hsrda.research.va.gov/publications/esp/esrd-depression.cfm. Accessed January 12, 2021.
17. Moher D, Liberati A, Tetzlaff J, Altman DG: The PRISMA Group: Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med 6: e1000097, 2009 10.1371/journal.pmed.1000097.
18. McGowan J, Sampson M, Salzwedel DM, Cogo E, Fowerster V, Lefebvre C: PRESS peer review of electronic search strategies: 2015 Guideline statement. J Clin Epidemiol 75: 40–46, 2016 https://doi.org/10.1016/j.jclinepi.2016.01.021.
19. Department of Veterans Affairs, Department of Defense: VA/DoD clinical practice guideline for the management of major depressive disorder. Version 3.0. Washington, D.C., Department of Veterans Affairs, Department of Defense, 2016.
20. Centers for Medicare and Medicaid Services Center for Clinical Standards & Quality: Summary of representative clinical depression screening tools. Centers for Medicare and Medicaid Services Center for Clinical Standards & Quality, 2015.
21. Furukawa TA, Reijnders M, Kishimoto S, Sakata M, DeRubeis RJ, Dimidjian S, Dozois DIA, Hegel UR, Collon SD, Carrett RB, Lespérance F, Segal ZV, Mohr DC, Simonson ADQ, Quilty LC, Reynolds CF, Gentili C, Leucht S, Engel JR, Cuijpers P: Translating the BDI and BDI-II into the HAMD and vice versa with equipercentile linking. Epidemiol Psychiatr Sci 29: e24, 2019 https://doi.org/10.1136/epidemipsych-2019-000088.
22. Stafford L, Berk M, Jackson HI: Validity of the hospital anxiety and depression scale and patient health questionnaire-9 to screen for depression in patients with coronary artery disease. Gen Hosp Psychiatry 29: 417–424, 2007 https://doi.org/10.1016/j.genhosppsych.2007.06.005.
23. Cameron IM, Crawford JR, Lawton K, Sharma S, Dutot S, Hay S, Reid IC: Applied Health Sciences (Mental Health): Assessing the validity of the PHQ-9, HADS, BDI-II and QIDS-SR in measuring severity of depression in a UK sample of primary care patients with a diagnosis of depression: Study protocol. Primary Care and Community Psychiatry 13: 67–71, 2008.
24. O’Connor E, Rossom RC, Henninger M, Groom HC, Burda BU, Henderson JT, Bigler KD, Whitlock EP: Screening for depression in adults: An updated systematic evidence review for the U.S. Preventive Services Task Force. Rockville, MD, Agency for Healthcare Research and Quality (US), 2016.
25. US Preventive Services Task Force: Appendix VII. Criteria for assessing external validity (Generalizability) of individual studies. 2017. Available at: https://www.uspreventiveservicestaskforce.org/uspstf/procedure-manual/procedure-manual-appendix-vii-criteria-considering-external-validity-generalizability-individual-studies. Accessed November 1, 2019.
26. US Preventive Services Task Force: Appendix VI. Criteria for assessing internal validity of individual studies, 2017. Available at: https://www.uspreventiveservicestaskforce.org/Page/Name/
58. Vangala C, Niu J, Montez-Rath ME, Yan J, Navaneethan SD, Winkelmayer WC: Selective serotonin reuptake inhibitor use and hip fracture risk among patients on hemodialysis. *Am J Kidney Dis* 75: 351–360, 2020 https://doi.org/10.1053/j.ajkd.2019.07.015

59. Palmer SC, Natale P, Ruospo M, Saglimbene VM, Rabindranath KS, Craig JC, Strippoli GF: Antidepressants for treating depression in adults with end-stage kidney disease treated with dialysis. *Cochrane Database Syst Rev* (5): CD004541, 2016 10.1002/14651858.CD004541.pub3

60. Covic A, Rastogi A: Hyperphosphatemia in patients with ESRD: Assessing the current evidence linking outcomes with treatment adherence. *BMC Nephrol* 14: 153, 2013 https://doi.org/10.1186/1471-2369-14-153

61. Natale P, Palmer SC, Ruospo M, Saglimbene VM, Rabindranath KS, Strippoli GF: Psychosocial interventions for preventing and treating depression in dialysis patients. *Cochrane Database of Syst Rev* 12: CD004542, 2019 https://doi.org/10.1002/14651858.CD004542.pub3

Received: May 19, 2020 Accepted: January 4, 2021